A Phase 1 Randomised, Double-blind, Placebo-controlled Single Ascending and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYNT-101 in Healthy Adults and Healthy Adults Who Are Overweight or Have Obesity
Latest Information Update: 05 Jan 2026
At a glance
- Drugs SYNT 101 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Syntis Bio
Most Recent Events
- 05 Jan 2026 New trial record